What are the side effects of Amycretin?
The most commonly reported Amycretin side effects are nausea (less than Semaglutide monotherapy in early data), reduced appetite, constipation. Most are mild and tend to be dose dependent. It is generally avoided with mTC / MEN-2 history. Human clinical evidence for Amycretin is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported Amycretin side effects
- Nausea (less than Semaglutide monotherapy in early data)
- Reduced appetite
- Constipation
Who should avoid it
- MTC / MEN-2 history
- Pancreatitis history
- Pregnancy / nursing
Bloodwork worth tracking
- Lipid panel
- A1C
- ALT/AST
References
- Amycretin (Novo Nordisk), early Phase 1/2 obesity readouts — Novo Nordisk pipeline, 2024-2025
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Dahl K et al., The Lancet, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human, phase 1 trial — Gasiorek A et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Amycretin
Last updated 2026-06-06.